Modality
Multispecific
MOA
EGFRi
Target
JAK1
Pathway
Sphingolipid
AMLOvarian Ca
Development Pipeline
Preclinical
~Oct 2023
→ ~Jan 2025
Phase 1
Apr 2025
→ May 2031
Phase 1Current
NCT06527382
1,169 pts·Ovarian Ca
2025-04→2031-05·Not yet recruiting
1,169 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-05-095.1y awayPh2 Data· Ovarian Ca
Trial Timeline
Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P1/2
Not yet…
Catalysts
Ph2 Data
2031-05-09 · 5.1y away
Ovarian Ca
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06527382 | Phase 1/2 | Ovarian Ca | Not yet recr... | 1169 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Niranesiran | Johnson & Johnson | Phase 2 | KIF18A | |
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| 207-2754 | Samsung Biologics | Phase 1/2 | KRASG12D | |
| Mavuratamab | Blueprint Medicines | NDA/BLA | BET | |
| Bemaderotide | Revolution Medicines | Phase 3 | BCL-2 | |
| Fixafutibatinib | Denali | Phase 3 | PRMT5 |